Mitralign attracts CV big guns in series C:
This article was originally published in Clinica
Mitralign, a Tewksbury, Massachusetts company developing a catheter-based technology for treating mitral valve regurgitation, has added Medtronic and Johnson & Johnson to its list of investors. The two medtech heavyweights led a $24m series C financing round, in which Mitralign also welcomed other new investors, including Oakwood Medical, Palisades Capital and Accelerated Technology Partners. Mitralign will use the funds to complete initial clinical studies and gain CE-marking for its system.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.